Varanou Jenkins Scientific Ltd
Registered name: VARANOU JENKINS SCIENTIFIC LTD
Varanou Jenkins Scientific Ltd does not publish its revenue or profit. Its accounts to 31 Mar 2025 show net assets of £21.
Varanou Jenkins Scientific Ltd did not publish its revenue or profit — small companies aren’t required to file a profit & loss account. Its accounts for the year to 31 Mar 2025 showed net assets of £21 and 0 employees. The company is classified under “research and experimental development on biotechnology” and is based in Henlow; we hold 4 years of its filed accounts.
- Status
- Active
- Location
- Henlow, East of England
- Age
- 9 yrs · since 2017
- Type
- Private Limited Company
Key figures
Revenue not disclosed
Varanou Jenkins Scientific Ltd’s accounts for the year to 31 Mar 2025 contain a balance sheet but no profit & loss account, so its revenue and profit are not public. UK small and micro-entity companies are not required to publish a P&L — this is normal and says nothing about how the business is performing.
We never estimate revenue. Below you’ll find the balance-sheet figures that were filed — useful as indirect signals of momentum, but they are not revenue or profit.
- Employees
- 0
- Net assets
- £21
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Mar 2022 | 31 Mar 2023 | 31 Mar 2024 | 31 Mar 2025 |
|---|---|---|---|---|
| Disclosure | Full P&L | Full P&L | Full P&L | No P&L |
| Profit & loss | ||||
| Revenue (turnover) | £0 | £0 | £0 | — |
| Cost of sales | £0 | £0 | £685 | — |
| Gross profit | £0 | £0 | −£685 | — |
| Operating profit | −£1.9k | −£78 | −£764 | — |
| Profit before tax | −£1.9k | −£78 | −£764 | — |
| Profit after tax | −£1.9k | −£78 | −£764 | — |
| Profit (best available) | −£1.9k | −£78 | −£764 | — |
| Employees (average) | 2 | 2 | 0 | 0 |
| Ratios | ||||
| Profit margin | — | — | — | — |
| Revenue per employee | £0 | £0 | — | — |
| Profit per employee | −£936 | −£39 | — | — |
| Growth (year on year) | ||||
| Headcount growth | — | 0% | ▼100% | — |
| Balance sheet — indirect signals, not revenue | ||||
| Cash at bank | £863 | £785 | £21 | £21 |
| Net assets | £863 | £785 | £21 | £21 |
| Current assets | £863 | £785 | £21 | £21 |
| Source | FullAccounts · bulk data Dec 2023 | FullAccounts · bulk data Dec 2023 | FullAccounts · bulk data Dec 2024 | FullAccounts · bulk data Dec 2025 |
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- 0%
- Now £21
- Cash at bank
- 0%
- Now £21
- Headcount
- —
- Now 0
- Deferred income
- —
- Now —
- Fixed assets
- —
- Now —
Similar profitable businesses
- Astex Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £404m
- Profit
- £283m
- Staff
- 183
- Amphista Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £33.9m
- Profit
- £19.8m
- Staff
- 56
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
- Qiagen Manchester LimitedManchester · Research and experimental development on biotechnology
- Revenue
- £53.7m
- Profit
- £11.8m
- Staff
- 239
- Alchemab Therapeutics LtdLondon · Research and experimental development on biotechnology
- Revenue
- £30m
- Profit
- £8.3m
- Staff
- 55
- Ligand UK Development LimitedLondon · Research and experimental development on biotechnology
- Revenue
- £8.7m
- Profit
- £6m
- Staff
- —
Sources
Latest figures from FullAccounts for the year to 31 Mar 2025, from the Companies House accounts bulk data published Dec 2025. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.